Celadon Pharmaceuticals Plc

CEL

GB00BDQYGP38

Pharmaceuticals

Delayed London S.E. Other stock markets 09:01:11 2024-05-01 am EDT			5-day change	1st Jan Change
105 ^GBX	+7.14%		-8.70%	-8.70%

Mar. 08	Celadon hails early results of chronic pain trial	AN
Mar. 07	Celadon Pharmaceuticals plc Announces the Results of an Early Economic Analysis of the Data Collected as Part of the Feasibility Study for Its Fully Approved Chronic Pain Clinical Trial	CI

Celadon Pharmaceuticals Plc Reports Earnings Results for the Half Year Ended June 30, 2023

September 28, 2023 at 02:00 am EDT

Celadon Pharmaceuticals Plc reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was GBP 0.008 million compared to GBP 0.011 million a year ago. Net loss was GBP 4.3 million compared to GBP 13.25 million a year ago.

Latest news about Celadon Pharmaceuticals Plc

Celadon hails early results of chronic pain trial	Mar. 08	AN
Celadon Pharmaceuticals plc Announces the Results of an Early Economic Analysis of the Data Collected as Part of the Feasibility Study for Its Fully Approved Chronic Pain Clinical Trial	Mar. 07	CI
Celadon announces start of cannabis supply for two UK companies	Dec. 14	AN
Celadon Delivers Pharmaceutical-grade Product Under Two Orders; Stock Rises	Dec. 14	MT
Celadon Pharmaceuticals plc Announces the First Supply of Its Pharmaceutical-Grade Product to the Two Commercial Contracts	Dec. 14	CI
Celadon Pharma raises GBP2.0 million via placing	Dec. 12	AN
Celadon Pharmaceuticals Raises GBP2 Million in Share Sale	Dec. 12	MT
Celadon Pharmaceuticals Wins Cannabis Product Supply Deal in Europe; Stock Surges	Nov. 16	MT
Celadon shares rise on supply contract worth up to GBP26 million	Nov. 16	AN
Celadon Pharmaceuticals plc Enters into Contract for the Commercial Supply of Its Pharmaceutical-Grade Cannabis Product with a Leading European Medicinal Cannabis Company	Nov. 16	CI
FTSE 100 Finishes Down as Energy Stocks Show Resilience	23-10-13	DJ
Celadon Pharmaceuticals raises GBP1.0 million through shares	23-10-13	AN
UK's Celadon Pharmaceuticals Raises GBP1 Million via Share Placing, Subscription	23-10-13	MT
Advanced Medical Solutions appoints non-executive director as chair	23-10-02	AN
Celadon Pharmaceuticals interim loss narrows; optimistic for future	23-09-28	AN
Earnings Flash (CEL.L) CELADON PHARMACEUTICALS Posts H1 Revenue GBP8,000	23-09-28	MT
Earnings Flash (CEL.L) CELADON PHARMACEUTICALS Posts H1 Loss GBX-7.20	23-09-28	MT
Celadon Pharmaceuticals Plc Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-28	CI
Celadon Pharmaceuticals Secures New Cannabis Product Deal in UK	23-09-05	MT
Celadon shares rise on second UK contract win for cannabis product	23-09-05	AN
Celadon Pharmaceuticals plc Enters into New Sales Contract with UK Pharmaceutical Company	23-09-05	CI
Celadon receives approval for 5,000 patient clinical cannabis trial	23-08-01	AN
Celadon Pharmaceuticals Plc Receives Approval to Roll-Out Chronic Pain Clinical Trial	23-08-01	CI
Celadon Pharmaceuticals loss widens; confident amid three-year deal	23-06-05	AN
Earnings Flash (CEL.L) CELADON PHARMACEUTICALS Reports FY22 Loss GBX-29.50	23-06-05	MT

Chart Celadon Pharmaceuticals Plc

Duration

Period

More charts

Company Profile

Celadon Pharmaceuticals Plc is a United Kingdom-based pharmaceutical company. The Company is engaged in research, cultivation, manufacturing, and supply of cannabinoid-based medicines. The Company is focused on growing indoor hydroponic cannabis initially for the chronic pain market. It is also focused on improving the quality of life for chronic pain sufferers, as well as exploring the potential of cannabinoid-based medicines for other conditions, such as autism. The Company's facility comprises an indoor hydroponic cultivation, proprietary GMP extraction and manufacturing and an analytical and R&D laboratory. It also has a minority interest in early-stage biopharma Kingdom therapeutics. The Company's subsidiary, LVL Health is a medical cannabis clinic for chronic pain that owns a medicines and healthcare products regulatory agency (MHRA) conditionally approved cannabis trial using cannabis-based medicinal products to treat chronic pain in the United Kingdom.

Sector

Pharmaceuticals

Calendar

2024-09-25 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.98 GBP

Average target price

2.35 GBP

Spread / Average Target

+139.80%

Consensus

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CELADON PHARMACEUTICALS PLC	-8.70%	78.81M
ELI LILLY AND COMPANY	+32.56%	704B
NOVO NORDISK A/S	+28.16%	577B
JOHNSON & JOHNSON	-4.33%	348B
MERCK & CO., INC.	+18.14%	327B
ABBVIE INC.	+4.72%	288B
ASTRAZENECA PLC	+14.91%	234B
NOVARTIS AG	+4.93%	198B
ROCHE HOLDING AG	-9.78%	194B
AMGEN INC.	-4.62%	147B

Other Pharmaceuticals